A study to evaluate safety and tolerability after oral dosing of AZD1656 in healthy volunteers

Study identifier:D1020C00001

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Randomized, Single-Blind, Placebo-Controlled, Single-Centre, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Interaction after Single Ascending Oral Doses of AZD1656 in Healthy Male Subjects

Medical condition

Healthy

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD1656

Sex

Male

Actual Enrollment

32

Study type

Interventional

Age

20 Years - 45 Years

Date

Study Start Date: 01 Jul 2008
Primary Completion Date: 01 Sept 2008
Study Completion Date: 01 Sept 2008

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Factorial Assignment
Masking: Single Blind
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria